4-(3-苯基甲氧基苯基)苯甲酸 | 122294-08-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-苯基甲氧基苯基)苯甲酸
• 英文名称: 3'-(phenylmethoxy)-1,1'-biphenyl-4-carboxylic acid
• 英文别名: 3'-benzyloxy-1,1'-biphenyl-4-carboxylic acid；3'-benzyloxy[1,1'-biphenyl]-4-carboxylic acid；3'-(Benzyloxy)[1,1'-biphenyl]-4-carboxylic acid；4-(3-phenylmethoxyphenyl)benzoic acid
• CAS: 122294-08-0
• 化学式: C₂₀H₁₆O₃
• 分子量: 304.345
• InChiKey: FLCMCDSGSVDXBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(3-苯基甲氧基苯基)苯甲酸 在 吡啶 、 草酰氯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 36.0h， 生成 3'-(phenylmethoxy)-N-<4-(3-pyridinyl)butyl>-1,1'-biphenyl-4-carboxamide
  参考文献：
  名称：

  Biphenylcarboxamide derivatives as antagonists of platelet-activating factor

  摘要：

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.

  DOI：

  10.1021/jm00128a025
• 作为产物：
  描述：

  3-苄氧基溴苯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 4-(3-苯基甲氧基苯基)苯甲酸
  参考文献：
  名称：

  Biphenylcarboxamide derivatives as antagonists of platelet-activating factor

  摘要：

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.

  DOI：

  10.1021/jm00128a025

文献信息

• Substituted n-[(pyridyl)alkyl]aryl-carboxamide
  申请人：Hoffmann-La Roche Inc.

  公开号：US04916145A1

  公开（公告）日：1990-04-10

  The invention relates to compounds of the formula ##STR1## wherein *B is ##STR2## Y is O or S, *A is *--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --, n or r, independently, are integers from 0 to 3, m is an integer from 0 to 1, provided that when m is 1, then n must be at least 1, X is O or S, R.sub.1 and R.sub.4, independently, are hydrogen, lower alkyl, hydroxy or lower alkoxy, provided that when *B is other than ##STR3## at least one of R.sub.1 and R.sub.4, and one of R.sub.6 and R.sub.7 must be hydrogen, R.sub.2 and R.sub.3 are independently hydrogen, lower alkyl, cycloalkyl, halogen, nitro, lower alkoxy, lower alkenyl, lower alkynyl or aryl, R.sub.5 and R.sub.6, independently are hydrogen or lower alkyl, R.sub.7 is hydrogen, lower alkyl, cycloalkyl or aryl, Het is a monocyclic 5- or 6-membered hetero aromatic or a bicyclic heteroaromatic radical containing one or two hetero atoms selected from nitrogen oxygen and sulfur, which radical may be substituted by lower alkyl, halogen or aryl, and the asterisk denotes the point of attachment, and when R.sub.6 and R.sub.7 are different, their enantiomers and racemic mixtures thereof, and pharmaceutical acceptable acid addition salts thereof. The compounds of formula I exhibit activity as Platelet Activating Factor (PAF) antagonists and are, therefore, useful as agents for the prevention and treatment of vascular diseases, pulmonary diseases, dermatological disorders, transplant rejection, immunological disorders and inflammatory conditions.

  该发明涉及以下式的化合物##STR1##其中*B为##STR2##Y为O或S，*A为*--(CH.sub.2).sub.n --(X).sub.m --(CH.sub.2).sub.r --，n或r独立地为0到3的整数，m为0到1的整数，但当m为1时，n必须至少为1，X为O或S，R.sub.1和R.sub.4独立地为氢、较低的烷基、羟基或较低的烷氧基，但当*B不是##STR3##时，R.sub.1和R.sub.4中至少一个，以及R.sub.6和R.sub.7中的一个必须为氢，R.sub.2和R.sub.3独立地为氢、较低的烷基、环烷基、卤素、硝基、较低的烷氧基、较低的烯基、较低的炔基或芳基，R.sub.5和R.sub.6独立地为氢或较低的烷基，R.sub.7为氢、较低的烷基、环烷基或芳基，Het为含有一或两个异原子（从氮、氧和硫中选择）的单环5-或6-成员杂芳基或含有一个或两个异原子的双环杂芳基，该基团可以被较低的烷基、卤素或芳基取代，星号表示连接点，当R.sub.6和R.sub.7不同时，它们的对映异构体和外消旋混合物，以及其药学上可接受的酸盐。式I的化合物表现为血小板活化因子（PAF）拮抗剂的活性，因此，它们可用作预防和治疗血管疾病、肺部疾病、皮肤病、移植排斥、免疫紊乱和炎症症状的药物。
• Unusual polymorphism in new bent-shaped liquid crystals based on biphenyl as a central molecular core
  作者：Anna Kovářová、Svatopluk Světlík、Václav Kozmík、Jiří Svoboda、Vladimíra Novotná、Damian Pociecha、Ewa Gorecka、Natalia Podoliak

  DOI：10.3762/bjoc.10.75

  日期：——

  Bent-shaped mesogens possessing a biphenyl as a central core have been synthesized and the role of the terminal chain and the orientation of the ester as a linkage group have been investigated. For the studied molecular core we have established that both parameters play an important role for the mesomorphic properties. The polyfluoroalkyl terminal chain supports the formation of mesophases, and the introduction of a chiral lactate terminal chain destabilizes mesophases for the first type of mutual orientation of ester groups, attached to the central core. On the contrary, for the opposite orientation of esters, the terminal chain has no effect on the mesomorphic properties, and columnar phases have been found for all compounds. A unique phase sequence has been found for the mesogen with the fluorinated chain. A generalized tilted smectics, SmC_G, have been observed in a temperature interval between two different lamellar SmCP phases and characterized by X-ray and dielectric measurements. The dielectric spectroscopy data are unique and presented for the first time in the SmC_G phase providing new information about the molecular dynamics.

  具有联苯作为中心核心的弯曲形态基团已被合成，并研究了末端链和酯作为连接基团的取向。针对所研究的分子核心，我们已经确定这两个参数对向列相性质起重要作用。多氟烷基末端链支持向列相的形成，而手性乳酸酯末端链的引入破坏了第一种酯基相互取向方式附着在中心核心上的向列相。相反，对于酯基的相反取向，末端链对向列相性质没有影响，并且所有化合物都发现了柱状相。对于具有氟化链的基团，发现了独特的相序列。在两种不同的层状SmCP相之间的温度区间内观察到了广义倾斜液晶相SmC_G，并通过X射线和介电测量进行了表征。介电谱数据是独特的，并首次在SmC_G相中提供了关于分子动力学的新信息。
• Piperazine derivatives as MAGL inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US11390610B2

  公开（公告）日：2022-07-19

  The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新杂环化合物或其药学上可接受的盐、 其中 R1、R2、X、Y1 和 Y2 如本文所述。
• TILLEY, JEFFERSON W.;CLADER, JOHN W.;ZAWOISKI, SONJA;WIRKUS, MARIA;LEMAHI+, J. MED. CHEM., 32,(1989) N, C. 1814-1820
  作者：TILLEY, JEFFERSON W.、CLADER, JOHN W.、ZAWOISKI, SONJA、WIRKUS, MARIA、LEMAHI+

  DOI：——

  日期：——
• PIPERAZINE DERIVATIVES AS MAGL INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3694840B1

  公开（公告）日：2021-08-04